Balloon Tamponade for Atonic Primary Postpartum Hemorrhage (UBT)
Primary Purpose
Postpartum Hemorrhage
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Bakri balloon
Condom loaded foley's catheter
Sponsored by
About this trial
This is an interventional treatment trial for Postpartum Hemorrhage focused on measuring condom-loaded Foley's catheter, Bakri balloon, primary atonic postpartum hemorrhage
Eligibility Criteria
Inclusion Criteria:
- Women who accept to participate (either the patient or her first-kin if she is unconscious)
- Primary atonic postpartum hemorrhage
Exclusion Criteria:
- Traumatic postpartum hemorrhage
- With any suspected (e.g. prolonged rupture of membranes) or clinical evidence of infection
- Pre eclampsia.
- Diabetes mellietus(DM) with pregnancy
- History of Deep venous thrombosis (DVT) or other thromboembolic complication
- Rheumatic heart patients
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Bakri balloon group
Condom loaded Foley's catheter group
Arm Description
The women in this group will be managed by Bakri balloon
The women in this group will be managed by condom loaded Foley's catheter
Outcomes
Primary Outcome Measures
Number of patients who need surgical intervention to stop the bleeding
Secondary Outcome Measures
Time between insertion and stoppage of bleeding (minutes)
Number of patients who need a blood transfusion
Number of patients who developed fever
The amount of blood loss (ml) after application of the balloon
Number of patients who referred to Intensive care unit
Number of patients who developed disseminated intravascular coagulopathy
Duration (minutes) of bleeding after deflation of the balloon
amount of bleeding (ml) after deflation of the balloon
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02430155
Brief Title
Balloon Tamponade for Atonic Primary Postpartum Hemorrhage
Acronym
UBT
Official Title
Comparison of Condom-Loaded Foley's Catheter Versus Bakri Balloon for Treatment of Primary Postpartum Hemorrhage: A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
July 2014 (Actual)
Primary Completion Date
July 1, 2015 (Actual)
Study Completion Date
March 4, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University
4. Oversight
5. Study Description
Brief Summary
Postpartum hemorrhage (PPH) is responsible for around 25% of maternal mortality worldwide reaching as high as 60% in some countries.PPH can also be a cause of long-term severe morbidity, and approximately 12% of women who survive PPH will have severe anemia.
Postpartum hemorrhage has been defined as blood loss in excess of 500 ml in a vaginal birth and in excess of 1 L in a cesarean delivery.For clinical purposes, any blood loss that has the potential to produce hemodynamic instability should be considered a PPH. However, clinical estimates of blood loss are often inaccurate. Primary (immediate) PPH occurs within the first 24 hours after delivery and approximately 70% of these cases are due to uterine atony. Furthermore, uterine tony is defined as the failure of the uterus to contract adequately after the child is born.
Guidelines for the management of postpartum hemorrhage (PPH) involve a stepwise approach including the exclusion of retained products of conception and genital tract trauma. Uterine atony, which is the most common cause, the management of uterine atony is an established stepwise protocol that in many international guidelines.
Uterine massage is recommended for the treatment of PPH. Initiate uterine massages soon as excessive bleeding/uterine atony is identified. Intravenous oxytocin alone still is the recommended uterotonic drug for the treatment of PPH.
If intravenous oxytocin is unavailable or if the bleeding does not respond to oxytocin, intravenous ergometrine, oxytocin-ergometrine fixed dose or a prostaglandin drug (including sublingual misoprostol, 600 mcg) should be given. The use of intrauterine balloon tamponade is recommended for the treatment of primary PPH due to uterine atony in women who do not respond to uterotonics or if uterotonics are not available.
Since 1983, when Goldrath published evidence that inserting a Foley catheter in the uterus and inflating it with water could achieve tamponade, case series and other studies have suggested that various uterine balloon tamponade(UBT) devices may be effective in treating PPH. The studies used various types of UBT devices, including a condom catheter, a Foley catheter, the Sengstaken-Blakemore Esophageal Tube, the Rusch Balloon, and the Bakri Uterine Balloon. In 2007, a systematic review of treatment options for PPH found that 84% success rate of UBT does not significantly vary from surgical treatment outcomes.The World Health Organization (WHO), the International Federation of Gynecology and Obstetrics (FIGO), the American College of Obstetricians and Gynecologists(ACOG), the Royal College of Obstetricians and Gynecologists(RCOG), and the International Confederation of Midwives (ICM) recognize balloon tamponade as a method that could significantly improve the management intractable PPH, especially in low-resource areas.
In 2012, WHO updated the guidelines for the management of PPH and retained placenta to include: "The use of intrauterine balloon tamponade is recommended for the treatment of PPH due to uterine atony. This recommendation is now stronger than the previous guidelines. It can be used for women who do not respond to uterotonics or if uterotonics are not available. This procedure potentially can avoid surgery and is appropriate while awaiting transfer to a higher-level facility".Furthermore, FIGO included UBT as a recommended second-line intervention for the treatment of PPH in their updated guidelines issued in 2012.
Bakri first published the concept of intrauterine balloon technology in the management of hemorrhage secondary to placenta praevia-accreta during caesarean section with or without bilateral hypo gastric arterial ligation.In 2006, the ACOG Practice Bulletin, published by the American College of Obstetricians and Gynecologists, made mention of the Bakri postpartum balloon for its specifically tailored design that enables conservative management of uterine bleeding in cases of uterine atony and other causes of PPH.
The idea of using a condom as a balloon tamponade was first generated and evaluated in Bangladesh by Sayeba Akhter to fill a need and in response to the high cost of commercially available UBT devices.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postpartum Hemorrhage
Keywords
condom-loaded Foley's catheter, Bakri balloon, primary atonic postpartum hemorrhage
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
66 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bakri balloon group
Arm Type
Active Comparator
Arm Description
The women in this group will be managed by Bakri balloon
Arm Title
Condom loaded Foley's catheter group
Arm Type
Active Comparator
Arm Description
The women in this group will be managed by condom loaded Foley's catheter
Intervention Type
Device
Intervention Name(s)
Bakri balloon
Intervention Description
is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
Intervention Type
Device
Intervention Name(s)
Condom loaded foley's catheter
Intervention Description
Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
Primary Outcome Measure Information:
Title
Number of patients who need surgical intervention to stop the bleeding
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Time between insertion and stoppage of bleeding (minutes)
Time Frame
1 year
Title
Number of patients who need a blood transfusion
Time Frame
1 year
Title
Number of patients who developed fever
Time Frame
1 year
Title
The amount of blood loss (ml) after application of the balloon
Time Frame
1 year
Title
Number of patients who referred to Intensive care unit
Time Frame
1 year
Title
Number of patients who developed disseminated intravascular coagulopathy
Time Frame
1 year
Title
Duration (minutes) of bleeding after deflation of the balloon
Time Frame
1 year
Title
amount of bleeding (ml) after deflation of the balloon
Time Frame
1 year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women who accept to participate (either the patient or her first-kin if she is unconscious)
Primary atonic postpartum hemorrhage
Exclusion Criteria:
Traumatic postpartum hemorrhage
With any suspected (e.g. prolonged rupture of membranes) or clinical evidence of infection
Pre eclampsia.
Diabetes mellietus(DM) with pregnancy
History of Deep venous thrombosis (DVT) or other thromboembolic complication
Rheumatic heart patients
12. IPD Sharing Statement
Citations:
PubMed Identifier
32609374
Citation
Kellie FJ, Wandabwa JN, Mousa HA, Weeks AD. Mechanical and surgical interventions for treating primary postpartum haemorrhage. Cochrane Database Syst Rev. 2020 Jul 1;7(7):CD013663. doi: 10.1002/14651858.CD013663.
Results Reference
derived
Learn more about this trial
Balloon Tamponade for Atonic Primary Postpartum Hemorrhage
We'll reach out to this number within 24 hrs